NGL Fine-Chem Ltd
Company Profile
Business description
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
Contact
301, E Square, Subhash Road
Vile Parle (East)
MumbaiMH400057
INDT: +91 2240842222
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2026
Employees
523
Stocks News & Analysis
stocks
Avoid this overpriced ASX share
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,924.20 | 8.30 | -0.09% |
| CAC 40 | 8,072.11 | 156.75 | 1.98% |
| DAX 40 | 23,982.85 | 573.48 | 2.45% |
| Dow JONES (US) | 47,740.80 | 239.25 | 0.50% |
| FTSE 100 | 10,428.25 | 178.73 | 1.74% |
| HKSE | 25,959.90 | 551.44 | 2.17% |
| NASDAQ | 22,695.95 | 308.27 | 1.38% |
| Nikkei 225 | 54,248.39 | 1,519.67 | 2.88% |
| NZX 50 Index | 13,094.37 | 4.46 | -0.03% |
| S&P 500 | 6,795.99 | 55.97 | 0.83% |
| S&P/ASX 200 | 8,692.60 | 11.80 | -0.14% |
| SSE Composite Index | 4,123.14 | 26.54 | 0.65% |